Every letter we have printed

I supply research peptides and I want to push back on the specification column point. We sell from a catalogue of six hundred products. Writing a meaningful individual specification for each would take a year of somebody’s time, and a generic one would be exactly the decorative limit your article criticises. What would you actually have us do?

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

I train four times a week, eat a hundred and sixty grams of protein and my appendicular lean mass has fallen by 1.8 kg over ten months while every lift has gone up. Your section on mass against function was the first thing I have read that made that seem normal rather than a failure.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.

Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.

A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.

The gallbladder section says some of the excess is attributable to weight loss rather than the drug. If the drug causes the weight loss, is that not a distinction without a difference for the person who ends up in theatre?

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

Nothing in your file addresses the social dimension, which for me was worse than the nausea. Six months of declining invitations to meals, and explaining to family why I was not eating. The tables do not have a row for that.

As a DXA technologist of twenty-two years I would add one thing to your precision section: the largest source of error in practice is not the machine, it is positioning. A patient scanned with their arms two centimetres further from their trunk will report different regional values. We are trained to a protocol and the protocol is not always followed.

The most useful sentence in the piece is the one saying a bad document is not a bad product. I have spent two years on forums watching people conclude the opposite from a missing signature block, and it has made the whole conversation about honesty rather than about paperwork.

I supply research peptides and I want to push back on the specification column point. We sell from a catalogue of six hundred products. Writing a meaningful individual specification for each would take a year of somebody’s time, and a generic one would be exactly the decorative limit your article criticises. What would you actually have us do?

You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.

A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?

As a DXA technologist of twenty-two years I would add one thing to your precision section: the largest source of error in practice is not the machine, it is positioning. A patient scanned with their arms two centimetres further from their trunk will report different regional values. We are trained to a protocol and the protocol is not always followed.

You write that no trial has measured strength. There are observational cohorts with grip strength data. Why do you insist on randomised measurement?

Your piece treats the one-quarter rule as discredited and then quotes fractions of one third and two fifths from the substudies as though those were more solid. They are group means from a hundred and forty people. Physician, heal thyself.

I train four times a week, eat a hundred and sixty grams of protein and my appendicular lean mass has fallen by 1.8 kg over ten months while every lift has gone up. Your section on mass against function was the first thing I have read that made that seem normal rather than a failure.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

You write that leucine and isoleucine cannot be distinguished by tandem mass spectrometry. That is too absolute. Side-chain fragmentation under high-energy conditions produces diagnostic w and d ions, and the discrimination has been demonstrated repeatedly.

I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?

You give the glutamine-to-lysine difference as 0.036 daltons and say it needs an orbital trap. In practice you also need the two species to be chromatographically separated or present in a sensible ratio, because at one per cent of the parent intensity the minor peak sits on the shoulder of the isotope envelope regardless of resolving power.

You describe the plateau as an energy-balance event and dismiss receptor desensitisation. Is there not a third possibility — that adherence quietly falls off at around a year and the plateau is partly a behavioural artefact of the trial rather than a physiological one?

You give the glutamine-to-lysine difference as 0.036 daltons and say it needs an orbital trap. In practice you also need the two species to be chromatographically separated or present in a sensible ratio, because at one per cent of the parent intensity the minor peak sits on the shoulder of the isotope envelope regardless of resolving power.

A small defence of the linear MALDI instrument. It is fast, it tolerates dirty samples, and for a synthesis chemist checking that a chain has grown by the residue intended it is entirely fit for purpose. The problem is not the instrument. It is printing its output on a release document.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

I stopped treatment fifteen weeks ago and my panel is worse than I expected. I had a panel at five weeks that looked fine and I had assumed I had escaped. Your point about the twelve-week timing was the explanation nobody offered me.

I stopped eight months ago after reaching a weight I was happy with, and I have regained four of the twenty-two kilograms I lost. Every article I read told me to expect two-thirds back. I am not complaining, but I would like to know whether I am unusual or whether the two-thirds figure was always a mean concealing an enormous range.